================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                ----------------

                                   FORM 10-QSB

                                ----------------
(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
    EXCHANGE ACT OF 1934

               For the quarterly period ended September, 30, 2006

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                            Commission File No. 09081

                                ----------------

                                   CYBRDI INC.
             (Exact name of registrant as specified in its charter)

                                ----------------

          CALIFORNIA                                              95-2461404
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

    401 Rosemont Ave. Frederick, MD                                 21701
(Address of principal executive office)                          (Zip Code)

       Registrant's telephone number, including area code: (301) 644-3901
                                                           --------------

                                       N/A
               Former name, former address and former fiscal year,
                         (if changed since last report)

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.                  Yes [ ]    No [X]

Indicate by a check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).                Yes [ ]    No [X]

Indicate by a check mark whether the registrant is a shell Company (as defined
by Rule 12b-2 of the Act).

                                                           Yes [ ]     No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock as of the latest practicable date:

50,456,569  shares of Common Stock, without par value, as of December 20, 2006

================================================================================
<PAGE>
                                      INDEX

                                                                          PAGES
                                                                          -----
PART I. - FINANCIAL INFORMATION

Item 1. Financial Statements

        Consolidated Balance Sheets as at September 30, 2006
        (unaudited) and December 31, 2005                                   4

        Cybrdi, Inc. and Subsidiary Consolidated Statements of
        Income and Comprehensive Income (Loss) (Unaudited) for
        Three Months and Nine Months Ended Sept 30, 2006 and 2005           5

        Consolidated Statements of Cash Flow (unaudited) for
        the nine months ended September 30, 2006 and 2005                   6

        Notes to Consolidated Financial Statements                          7

Item 2.  Management's Discussion and Analysis of Financial Condition
         and Results of Operation                                          11

Item 3.  Quantitative and Qualitative Disclosures about Market Risk        17

Item 4.  Controls and Procedures                                           17

PART II. - OTHER INFORMATION

Item 1.  Legal Proceedings                                                 18

Item 2.  Unregistered Sales of Equity Securities                           18

Item 3.  Defaults upon senior securities                                   18

Item 4.  Submission of matters to a vote of security holders               18

Item 5.  Exhibits and reports on Form 8-K                                  18

                                       2
<PAGE>

                           FORWARD LOOKING STATEMENTS

         This Quarterly Report on Form 10-QSB for the quarterly period ended
September 30, 2006 contains "forward-looking statements". Generally, the words
"believes", "anticipates," "may," "will," "should," "expect," "intend,"
"estimate," "continue," and similar expressions or the negative thereof or
comparable terminology are intended to identify forward-looking statements which
include, but are not limited to, statements concerning the Company's
expectations regarding its working capital requirements, financing requirements,
business prospects, and other statements of expectations, beliefs, future plans
and strategies, anticipated events or trends, and similar expressions concerning
matters that are not historical facts. Such statements are subject to certain
risks and uncertainties, including the matters set forth in this Quarterly
Report or other reports or documents the Company files with the Securities and
Exchange Commission from time to time, which could cause actual results or
outcomes to differ materially from those projected. Undue reliance should not be
placed on these forward-looking statements which speak only as of the date
hereof. The Company undertakes no obligation to update these forward-looking
statements. In addition, the forward-looking statements in this Quarterly Report
on Form 10-QSB involve known and unknown risks, uncertainties and other factors
that could cause the actual results, performance or achievements of the Company
to differ materially from those expressed in or implied by the forward-looking
statements contained herein.


Item 1A.  RISK FACTORS

         There have been no material changes in our risk factors from those
disclosed in our 2005 Annual Report on Form 10-K.










                                       3

<PAGE>

                         PART I. FINANCIAL INFORMATION


Item 1.  Financial Statements



CYBRDI, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2006 AND DECEMBER 31, 2005
-------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                             SEPT 30,      DEC 31,
                                                                               2006         2005
                                                                            ----------   ----------
                                                                             UNAUDITED     AUDITED
<S>                                                                         <C>          <C>
                                     ASSETS
CURRENT ASSETS
     Cash and equivalents                                                   $  859,609   $4,206,695
     Accounts receivable                                                         5,581      360,503
     Inventories                                                               318,599      263,634
     Loan to unaffiliated company                                            3,200,911           --
     Other receivables and prepaid expenses                                    253,411       96,626
                                                                            ----------   ----------
TOTAL CURRENT ASSETS                                                         4,638,111    4,927,458
PROPERTY, PLANT AND EQUIPMENT, NET                                             511,720      553,382
INTANGIBLE ASSETS (NET)                                                        533,094      581,593
DEFERRED TAX ASSETS                                                             42,065       41,199
                                                                            ----------   ----------

TOTAL ASSETS                                                                 5,724,990    6,103,632
                                                                            ==========   ==========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
     Accounts payable and accrued expenses                                      72,801       34,118
     Other payables                                                             72,055       51,193
     Amount due to stockholders                                                232,013      645,021
                                                                            ----------   ----------
TOTAL CURRENT LIABILITITES                                                     376,869      730,332

MINORITY INTERESTS                                                           1,143,899    1,149,158
                                                                            ----------   ----------

TOTAL LIABILITIES                                                            1,520,768    1,879,490
                                                                            ----------   ----------

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
     Preferred Stock, $1.00 per value, 500,000 shares authorized,
        zero shares issued and outstanding                                          --           --
     Common Stock, no par value, 150,000,000 shares authorized,
        50,456,569 shares issued and outstanding as of September 30, 2006
        and December 31, 2005                                                       --           --
     Additional paid-in capital                                              3,601,932    3,601,932
     Reserve funds                                                             336,885      336,885
     Retained earnings                                                          77,972      174,416
     Accumulated other comprehensive income                                    187,433      110,909
                                                                            ----------   ----------
TOTAL STOCKHOLDERS' EQUITY                                                   4,204,222    4,224,142

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                  $5,724,990   $6,103,632
                                                                            ==========   ==========
</TABLE>


                 The accompanying notes are an integral part of
                    these consolidated financial statements.

                                        4

<PAGE>

CYBRDI, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
FOR THREE MONTHS AND NINE MONTHS ENDED SEPT 30, 2006 AND 2005
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                 THREE MONTHS     THREE MONTHS    NINE MONTHS      NINE MONTHS
                                                     ENDED           ENDED           ENDED            ENDED
                                                   SEPT 30,         SEPT 30,        SEPT 30,         SEPT 30,
                                                     2006             2005            2006             2005
                                                 ------------     ------------    ------------     ------------
                                                   UNAUDITED        UNAUDITED       UNAUDITED        UNAUDITED
<S>                                              <C>              <C>             <C>              <C>
Revenue
       Products                                  $    118,063     $    280,952    $    291,651     $    957,161
       Service rendered                                30,740           34,360          84,611          116,030
                                                 ------------     ------------    ------------     ------------
          TOTAL REVENUE                               148,803          315,312         376,262        1,073,191
                                                 ------------     ------------    ------------     ------------
COST OF SALES
       Products                                        48,292           50,243         138,837          158,118
       Service rendered                                (1,763)           3,025           3,417           11,677
                                                 ------------     ------------    ------------     ------------
         TOTAL COST OF SALES                           46,529           53,268         142,254          169,795
                                                 ------------     ------------    ------------     ------------
GROSS PROFIT                                          102,274          262,044         234,008          903,396
                                                 ------------     ------------    ------------     ------------

OPERATING EXPENSES:
       Selling and distribution expenses               25,863           13,080          84,510           54,854
       General and administrative expenses            138,797          188,777         457,560          511,831
                                                 ------------     ------------    ------------     ------------
TOTAL OPERATING EXPENSES                              164,660          201,857         542,070          566,685
                                                 ------------     ------------    ------------     ------------

(LOSS) INCOME FROM OPERATIONS                         (62,386)          60,187        (308,062)         336,711
                                                 ------------     ------------    ------------     ------------
OTHER INCOME/(EXPENSE)
       Interest income                                 64,745              533         195,696            2,529
       Other (expense)/income, net                      3,187           52,605          10,663           51,450
                                                 ------------     ------------    ------------     ------------
TOTAL OTHER (EXPENSE)/ INCOME                          67,932           53,138         206,359           53,979
                                                 ------------     ------------    ------------     ------------

INCOME BEFORE INCOME TAXES                              5,546          113,325        (101,703)         390,690
Income taxes (expenses)/benefit                            --           10,221              --           34,694
                                                 ------------     ------------    ------------     ------------
Income before minority interest                         5,546          103,104        (101,703)         355,996
Minority Interest                                      (1,509)          23,568          (5,259)          82,760
                                                 ------------     ------------    ------------     ------------

NET INCOME (LOSS)                                $      7,055     $     79,536    $    (96,444)    $    273,236
                                                 ------------     ------------    ------------     ------------

Other comprehensive loss:
Foreign currency translation gain                      41,896           90,091          76,524           90,077
                                                 ------------     ------------    ------------     ------------

COMPREHENSIVE INCOME (LOSS)                      $     48,951     $    169,627    $    (19,920)    $    363,313
                                                 ============     ============    ============     ============


Weighted average number of shares outstanding      50,456,569       50,456,569      50,456,569       50,456,569
                                                 ============     ============    ============     ============

Earnings per share, basic and diluted            $       0.00     $       0.00    $      (0.00)    $       0.01
                                                 ============     ============    ============     ============
</TABLE>



                 The accompanying notes are an integral part of
                    these consolidated financial statements.

                                        5

<PAGE>

CYBRDI INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE NINE MONTHS ENDED SEPT 30, 2006 AND 2005
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                NINE MONTHS     NINE MONTHS
                                                                   ENDED           ENDED
                                                                  SEPT 30,        SEPT 30,
                                                                   2006            2005
                                                                -----------     -----------
                                                                 UNAUDITED       UNAUDITED
<S>                                                             <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
      Net (loss) income                                         $   (96,444)    $   273,236
      Adjustments to reconcile net (loss) income to net cash
        provided by operating activities:
      Depreciation and amortization                                 154,315         178,267
      Minority interest's share of net (loss) income                 (5,259)         82,760
CHANGES IN OPERATING ASSETS AND LIABILITIES:
      Accounts receivable, net                                      355,037        (338,076)
      Inventories                                                   (48,404)          6,419
      Other receivable and prepaid expenses                        (151,566)       (137,448)
      Accounts payable and accrued expenses                          37,184           9,770
      Other payables and liabilities                                 19,378         (12,806)
      Customer Deposit                                                   --           6,835
                                                                -----------     -----------
      Net cash provided by operating activities                     264,241          68,957
                                                                -----------     -----------

CASH FLOWS FROM INVESTING ACTIVITIES
      Purchase of property, plant and equipment                     (42,637)        (15,623)
      Loan to unaffiliated companies                             (3,200,911)             --
                                                                -----------     -----------
      Net cash used in investing activities                      (3,243,548)        (15,623)
                                                                -----------     -----------

CASH FLOWS FROM FINANCING ACTIVITIES
      Proceeds advanced from shareholders                             1,000          89,182
      Repayment of advanced to shareholder                         (411,655)             --
      Payment of dividend                                                --        (138,508)
      Payment for merger expenses                                        --        (200,168)
                                                                -----------     -----------
      Net cash used in financing activities                        (410,655)       (249,494)
                                                                -----------     -----------

NET (DECREASE) INCREASE IN CASH AND EQUIVALENTS                  (3,389,962)       (196,160)
      Effect of exchange rate changes on cash                        42,876          58,120
      Cash and equivalents, at beginning of period                4,206,695       3,899,706
                                                                -----------     -----------

CASH AND EQUIVALENTS, AT END OF PERIOD                          $   859,609     $ 3,761,666
                                                                ===========     ===========
</TABLE>


                 The accompanying notes are an integral part of
                    these consolidated financial statements.

                                        6

<PAGE>

                                  CYBRDI, INC.
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
            FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2006 (UNAUDITED)

NOTE A - BASIS OF PRESENTATION

Interim financial statements:

The accompanying financial statements and footnotes have been condensed and
therefore do not contain all disclosures required by generally accepted
accounting principles. The interim financial statements are unaudited; however,
in the opinion of Cybrdi Inc. (the "Company"), the interim financial statements
include all adjustments, consisting only of normal recurring adjustments,
necessary for a fair statement of the results for the interim periods. Results
for interim periods are not necessarily indicative of those to be expected for
the full year. It is suggested that these condensed consolidated financial
statements be read in conjunction with the December 31, 2005 audited
consolidated financial statements and the accompanying notes thereto.

Description of business and revenue recognition:

On April 2, 2005 the Company filed amendments to its articles of incorporation
to change its name from Certron Corporation to Cybrdi, Inc. The amendment was
approved by the required vote of shareholders in accordance with Section 902 and
Section 903 of the California Corporations Code.

Until its acquisition of Cybrdi, Inc. on February 10, 2005, the Company's
business consisted primarily of the distribution of magnetic media products.
With the completion of the merger, all the magnetic media distribution business
activities have ceased and Certron's sole business is conducted through Cybrdi.
Cybrdi's focus is the field of biogenetics commercialization, specializing in
the rapid introduction of tissue microarray products and services in both the
international and Chinese markets.

Most of the Company's activities are conducted through its 80% equity ownership
in China Shaanxi Shaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a
sino-foreign equity joint venture established in July 2000 in the People's
Republic of China. The Company, with its principal operations located in China,
aims to take advantage of China's abundant scientific talent, low wage rates,
less stringent biogenetic regulation, and the huge genetic population as it
introduces its growing list of tissue microarray products.

Revenue represents the invoiced value of goods sold recognized upon the delivery
of goods to customers and service income is recognized when services are
provided. Deferred revenue represents the undelivered portion of invoiced value
of goods sold to customers. Sales transactions not meeting all the conditions of
the full accrual method are accounted for using the deposit method of
accounting. Under the deposit method, all costs are capitalized as incurred, and
payments received from the buyer are recorded as customer deposits.

Reverse merger:

On February 10, 2005, (the "Closing Date") the Company closed on an Agreement
and Plan of Merger (the "Agreement") among Certron Corporation ("Certron"), a
California corporation, Certron Acquisition Corp., a Maryland corporation and a
wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a
Maryland corporation ("Cybrdi - Maryland") relating to the acquisition by
Certron of all of the issued and outstanding capital stock of Cybrdi - Maryland
in exchange for shares of common stock of Certron that will aggregate
approximately 93.8% of the issued and outstanding common stock of Certron.
Pursuant to the terms of the Agreement, at the Closing Date (a) Acquisition Sub
has been merged with and into Cybrdi - Maryland, with Cybrdi - Maryland being
the surviving corporation, (b) the common stock of Cybrdi-Maryland has been
cancelled and converted into the right to receive shares of the common stock of
Certron at an exchange ratio of 1.566641609. This resulted in the issuance of
47,328,263 shares of the Certron's common stock , and (c) each share of the
common stock of Acquisition Sub has been converted in to and become one share of
the common stock of Cybrdi-Maryland. The share exchange has been accounted for
as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi
Inc. will be treated as the continuing entity for accounting purposes and the
historical financial statements presented will be those of Cybrdi, Inc.

                                       7
<PAGE>

In connection with the Agreement, on February 10, 2005, the Company amended its
articles of incorporation to authorize the issuance of 150 million shares of
common stock no par value and 500,000 shares of preferred stock, $1.00 par value
per share, none of which are issued or outstanding.

Concurrent with the filing of the Articles of Merger, all of the Company's then
existing officers and directors tendered their resignation and Yanbiao Bai was
appointed as our Chairman of the Board of Directors. Mr. Bai then nominated the
following individuals to serve on the Board of Directors: Lei Liu, James Pan,
Xue Bu, Lieping Chen and MinMin Qin. The new Directors subsequently elected Dr.
Lei Liu as Chief Executive Officer, Mr. Yanbiao Bai as President, and Mrs. Xue
Bu as Secretary and Treasurer. Lieping Chen and James Pan have since tendered
their resignations as directors of the Company and Lei Liu has resigned as the
Chief Executive Officer.

On March 31, 2005 the Company's Board of Directors changed its fiscal year end
from October 31 to December 31. Certron's fiscal year end was changed to
correspond with the fiscal year end of Cybrdi - Maryland.

Principles of consolidation:

The condensed consolidated financial statements include the accounts of Cybrdi,
Inc. and its wholly-owned subsidiaries and joint ventures.

All significant intercompany balances and transactions have been eliminated.

Recent Accounting Pronouncements:
In June 2006, the FASB issued Statement of Financial Accounting Standards
Interpretation Number 48, "Accounting for Uncertainty in Income Taxes"
("FIN48"). FIN 48 provides clarification regarding the accounting for
uncertainty in income taxes recognized in an enterprise's financial statements
in accordance with FASB Statement No. 109, "Accounting for Income Taxes". FIN 48
is effective for fiscal years beginning after December 15, 2006. The Company is
currently evaluating the impact of FIN48 on its financial statements.

In May 2005, the FASB issued Statement No. 154, "Accounting Changes and Error
Corrections" ("FAS 154"). FAS 154 generally require that accounting changes and
errors be applied retrospectively. FAS 154 is effective for accounting changes
and corrections of errors made in fiscal years beginning after December 15,
2005. The Company does not expect FAS 154 to have a material impact on its
financial statements.

In March 2005, the FASB issued Statement of Financial Accounting Standards
Interpretation Number 47, "Accounting for Conditional Asset Retirement
Obligations" ("FIN 47"). FIN 47 provides clarification regarding the meaning of
the term "conditional asset retirement obligation" as used in FASB Statement No.
143, "Accounting for Asset Retirement Obligations." FIN 47 is effective for
fiscal years beginning after December 15, 2005. The Company is currently
evaluating the impact of FIN 47 on its financial statements.

On December 16, 2004, the Financial Accounting Standards Board ("FASB")
published Statement of Financial Accounting Standards No. 123 (Revised 2004),
Share-Based Payment ("SFAS 123R"). SFAS 123R requires that compensation cost
related to share-based payment transactions be recognized in the financial
statements. Share-based payment transactions within the scope of SFAS 123R
include stock options, restricted stock plans, performance-based awards, stock
appreciation rights, and employee share purchase plans. This standard will be
effective for awards granted, modified or settled in fiscal years beginning
after June 15, 2005. Accordingly, the Company will implement the revised
standard in the first quarter of fiscal year 2006. Management is assessing the
implications of this revised standard, which may materially impact the Company's
results of operations in fiscal year 2006 and thereafter.

NOTE B - ASSETS

The September 30, 2006 balance sheet included total current assets of $4,638,111
and non-current assets of $1,086,879. Of these amounts, approximately $859,609
in cash and $5,581 in accounts receivable are planned for funding current
operations and for future business expansion.

                                       8
<PAGE>

Other current assets also included inventories, loan to unaffiliated company,
and other receivable and prepaid expenses. Inventories are mainly finished goods
and very few raw materials. Inventories are stated at the lower of cost or
market. Cost of raw materials is determined on the basis of first in first out
method ("FIFO"). Finished goods are determined on the weighted average basis and
are comprised of direct materials, direct labor and an appropriate proportion of
overhead. The other primary asset included in-current assets is loan to
unaffiliated company. Loan to unaffiliated company consists of loans to Xi'an
QuanYe Security Co., Ltd ("QuanYe"), an unrelated People's Republic of China
("PRC") registered company located in Xian PRC. QuanYe is engaged in the
pawnshop business and their primary business is offering alternative financing
to small local companies. According to the loan agreement, QuanYe has received
loans from Chaoying Biotech of a total amount of RMB29.3Million (equivalent to
$3,654,870), since January 2006. As of September 30, 2006, the loans balance had
been reduced to RMB25.3 Million (equivalent to $3,200,911) and the details are
listed as follows:

<TABLE>
<CAPTION>
-------------------- --------------------------------- --------------- ------------------- ---------------------
    Contract                       Loan Amount            Interest            Term              Repayment
 Executed Date
-------------------- ------------------ -------------- --------------- ------------------- ---------------------
<S>                     <C>                <C>               <C>            <C>                 <C>
     1/9/2006           RMB 15,000,000     $1,871,094        8%              1 year             11/16/2006
-------------------- ------------------ -------------- --------------- ------------------- ---------------------
     1/10/2006           RMB 8,300,000     $1,035,338        8%              1 year             11/25/2006
-------------------- ------------------ -------------- --------------- ------------------- ---------------------
     1/19/2006           RMB 6,000,000      $ 748,438        5%             3 months                **
-------------------- ------------------ -------------- --------------- ------------------- ---------------------
</TABLE>

** RMB1 million (equivalent to $124,740) , RMB2 million (equivalent to
   $249,479), and RMB1 million (Around $126,518)was repaid on April 28, 2006,
   June 19, 2006, and August 16, 2006 respectively. Loan of RMB 2 million
   (equivalent to $253,036) was extended to December 31, 2006 with an annual
   interest rate of 5%

Management believes and views QuanYe as an alternative financial institution and
it is an optimal way to use its cash on hand. The regular market interest rate
in the PRC is 0.72% per annum. Cybrdi expects to obtain higher interest income
for its unused fund through these types of loan arrangements. However, these
advances are unsecured and have a default risk higher than a bank deposit.

Included in-non-current assets are property, plant and equipment, intangible
assets, and deferred tax assets. Property, plant and equipment mainly consist of
building, motor vehicles, leasehold improvement, software-website, and machinery
used for product manufacturing located in the People's Republic of China
("PRC"), and office equipments located in PRC and United States. Depreciation
on property, plant and equipment is computed using the straight -line method
over the estimated useful life of the assets. The majority of the assets have
estimated useful lives of 10 years. Building and office equipments have
estimated useful lives of 20 and 5 years, respectively. Intangible assets
include a patent. Effective January 1, 2002, with the adoption of SFAS No. 142,
intangible assets with a definite life are amortized on a straight-line basis.
The patent is being amortized over its estimated life of 10 years.

NOTE C - LIABILITIES

The September 30, 2006 balance sheet included total liabilities of $1,520,768 of
which $1,143,899 represents the 20% minority interest in Chaoying Biotech.
Included in the total liabilities $232,013 was due to stockholders who are also
officers of the Company. The amount is an advance to the Company to assist with
operations. This advance is non-interest bearing and has no set repayment terms.


                                       9
<PAGE>

In accordance with the relevant tax laws and regulations of the PRC, Chaoying
Biotech is entitled to full exemption from Corporation Income Tax ("CIT") for
the first two years and a 50% reduction in CIT for the next three years,
commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, the Company begins to record 50% CIT provision for first
quarter of 2005. The effective tax rate is approximately 7.5%. There is no tax
provision for the quarter ended September 30, 2006, since there is a loss for
the Company's third quarter in 2006.

NOTE D - STOCKHOLDERS' EQUITY

As a result of the reverse merger (see Note A), the common stock of
Cybrdi-Maryland has been cancelled and converted into shares of common stock of
Certron at an exchange ratio of 1.566641609. This resulted in the issuance of
47,328,263 shares of Certron's common stock to the Cybrdi shareholders. As of
September 30, 2006, the Company had 50,456,569 shares of common stock issued and
outstanding. Historical information of the surviving company is that of Cybrdi -
Maryland.

NOTE E - LEGAL PROCEEDINGS

There is no material pending legal proceedings to which the Company is a party.
The Company was notified by a letter dated June 2, 2000 received June 6, 2000
that the Company may have a potential liability from waste disposal in the
Casmalia Disposal Site at Santa Barbara County, California. The Company was
given a choice of either signing an agreement that would toll the statute of
limitations for eighteen (18) months in order to allow the Company to resolve
any liability with the government without incurring costs associated with being
named a defendant in a lawsuit, or becoming an immediate defendant in a lawsuit.
The Company signed the tolling agreement. On November 20, 2001, the tolling
agreement was extended for an additional 18 months. On May 20, 2003 the tolling
agreement was again extended for an additional 18 months and on November 24,
2004 the tolling agreement was again extended for additional 18 months. On June
29, 2004, the Company received a proposed settlement from the EPA in the amount
of $21,131. The Company is waiting for communication from the government
concerning payment of the proposed settlement. As of September 30, 2006, the
Company has accrued a sufficient amount to cover any potential liabilities from
this matter.




                                       10

<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition and
         Results of Operation

The following discussion and analysis should be read in conjunction with our
Financial Statements and Notes thereto appearing elsewhere in this Report on
Form 10-QSB as well as our other SEC filings.

Plan of Operations

With the completion of the merger, management determined to discontinue
Certron's prior business operations, the sale of magnetic media distribution
tapes and products, and pursue business opportunities through Cybrdi, Inc. Most
of Cybrdi's activities are conducted through its 80% equity ownership in China
Shaanxi Shaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a sino-foreign
equity joint venture established in July 2000 in the People's Republic of China.
Cybrdi became affiliated with Chaoying Biotech in March 2003. The Chaoying
Biotech joint venture agreement has a term of 15 years. The term of joint
venture may be extended upon the mutual consent of the parties.

The Company focuses on biogenetics commercialization. The business includes
sales of tissue microarray products and services. Tissue chips, also called
microtissue arrays, represent a newly developed technology providing
high-throughput molecular profiling and parallel analysis of biological and
molecular characteristics for hundreds of pathologically controlled tissue
specimens. Tissue arrays can provide rapid and cost-effective localization and
evaluation of proteins, RNA, or DNA molecules, which is particularly useful for
functioning genomic studies. Cybrdi manufactures both human and animal tissue
microarrays for a wide variety of scientific uses, including drug discovery and
development purposes.

Our principal operations are located in Shaanxi China, where we aim to take
advantage of China's abundant scientific talent, low wage rates, less stringent
biogenetic regulation, and the huge genetic population as it introduces its
growing list of tissue microarray products.






                                       11

<PAGE>

RESULTS OF OPERATIONS

THE FOLLOWING TABLE SETS FORTH CERTAIN ITEMS IN OUR UNAUDITED CONSOLIDATED
STATEMENTS OF OPERATIONS (UNAUDITED) FOR THE THREE MONTHS ENDED SEPTEMBER 30,
2006 AND, 2005.

<TABLE>
<CAPTION>
                                             FOR THREE MONTHS         FOR THREE MONTHS
                                                 ENDED                    ENDED
                                                SEPT 30,                 SEPT 30,
                                                  2006                     2005                 2006 VS 2005
                                              ----------                ----------              ------------
                                              (UNAUDITED)               (UNAUDITED)         INCREASE/ (DECREASE)
<S>                                            <C>        <C>           <C>          <C>        <C>               <C>
Revenue
      Products                                $  118,063    79%         $  280,952    89%       $  (162,889)       -58%
      Service rendered                            30,740    21%             34,360    11%            (3,620)       -11%
                                              ----------                ----------              -----------
         Total revenue                           148,803   100%            315,312   100%          (166,509)       -53%
                                              ----------                ----------              -----------
Cost of sales
      Products                                    48,292                    50,243                   (1,951)        -4%
      Service rendered                            (1,763)                    3,025                   (4,788)      -158%
                                              ----------                ----------              -----------
        Total cost of sales                       46,529    31%             53,268     5%            (6,739)       -13%
                                              ----------                ----------              -----------
Gross profit                                     102,274    69%            262,044    83%          (159,770)       -61%
                                              ----------                ----------              -----------

Operating expenses:
      Selling and distribution expenses           25,863                    13,080                   12,783         98%
      General and administrative expenses        138,797                   188,777                  (49,980)       -26%
                                              ----------                ----------              -----------
Total operating expenses                         164,660   111%            201,857    19%           (37,197)       -18%
                                              ----------                ----------              -----------

Income from operations                           (62,386)  -42%             60,187     6%          (122,573)      -204%
                                              ----------                ----------              -----------
Other income/(expense)
      Interest income                             64,745                       533                   64,212      12047%
      Other (expense)/income, net                  3,187                    52,605                  (49,418)       -94%
                                              ----------                ----------              -----------
Total other (expense)/ income                     67,932    46%             53,138     5%            14,794         28%
                                              ----------                ----------              -----------

Income before income taxes                         5,546                   113,325                 (107,779)       -95%
Income taxes (expenses)/benefit                       --                    10,221                  (10,221)
                                              ----------                ----------              -----------
Income before minority interest                    5,546     4%            103,104    10%           (97,558)       -95%
Minority Interest                                 (1,509)   -1%             23,568     2%           (25,077)      -106%
                                              ----------                ----------              -----------
Net income                                    $   7,055      5%         $   79,536     7%       $   (72,481)       -91%
                                              ----------                ----------              -----------
</TABLE>

THREE MONTHS ENDED SEPTEMBER 30, 2006 COMPARED TO
THREE MONTHS ENDED SEPTEMBER 30, 2005

Net Sales

Cybrdi generates two categories of revenues: tissue chip product and services.
The net sales decrease to $148,803 for the three months ended September 30, 2006
from $315,312 for the three months ended September 30, 2005.


                                       12
<PAGE>

Tissue Chip Product: sales decreased along all product lines in the tissue chip
business. The net sales decreased $162,889 to $118,063 for the three months
ended September 30, 2006 as compared to $280,952 for the three months ended
September 30, 2005. The decrease in net sales of our Tissue Chip business is
primarily attributable to the company's new sales policy of restricting the
sales to certain existing customers in China with significantly delinquent past
due amounts. The decrease is partially offset by an increase in international
sales. Sales volume for Tissue Chip Products in China has dropped for the three
months ended September 30, 2006 as compared to September 30, 2005. International
sales volume increased for the three months ended September 30, 2006 as compared
to September 30, 2005.

Services: Fewer technical service orders were received during the third quarter
of 2006 as compared to 2005 resulting in a decrease in sales of $3,620 to
$30,740 from $34,360 for the three months ended September 30, 2006 as compared
to September 30, 2005.

Gross Margin

Gross margin as a percent of sales was69% and 83% for the three months ended
September 30, 2006 and 2005, respectively. Gross profit for the three months
ended September 30, 2006 decreased to $102,274 from $262,044 for the three
months ended September 30, 2005. The primary reason for the decrease is due to
decreased sales of Tissue Chip Products in China, due to the Company new sales
policy, which was partially offset by increased international sales of Tissue
Chip Products. The gross margin decrease was primarily due to the reduction in
units of product sales.

Operating Expenses

Our operating expenses decreased to $164,660 for the three months ended
September 30, 2006 from $201,857 for the three months ended September 30, 2005.
This is primarily due to an decrease in general and administrative expenses of
$49,980 to $138,797 for the three months ended September 30, 2006 from $188,777
for the three months ended September 30, 2005. This decrease was offset by an an
increase in selling and distribution expenses of $12,783 to 25,863 for the three
months ended September 30, 2006 from $13,080 for the three months ended
September 30, 2005. The decrease in general and administrative expenses was
primarily due to the reduction of office expenses, consulting fee, professional
expenses, and depreciation for deferred assets in year 2006. The increase in
selling expenses is primary due to the membership fee $11,386 (RMB91,185)
allocated from Tinmei Lelier Slim Body Medical Tech in the third quarter of 2006
for the Company to use Lelier's trade mark, technology and products. The
effective period for this membership is from November 10th 2005 to December 31,
2007. For the period from November 10th 2005 (date of membership start) to
September 30, 2006, the Company did not generate any income from this
membership.

Income Taxes

The Company has not recorded a provision for federal income tax for quarter
ended September 30, 2006 due to no taxable income in year 2006. In accordance
with the relevant tax laws and regulations of the People's Republic of China,
Chaoying Biotech is entitled to full exemption from Corporation Income Tax
("CIT") for the first two years and a 50% reduction in CIT for the next three
years, commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, the Company begins to record 50% CIT provision from the
first quarter of 2005. The effective income tax rate is 7.5% for the quarter
ended September 30, 2006 and 2005. Due to operating losses for the third quarter
2006, the Company does not need to pay income tax for the quarter ended
September 30, 2006.

                                       13
<PAGE>

THE FOLLOWING TABLE SETS FORTH CERTAIN ITEMS IN OUR UNAUDITED CONSOLIDATED
STATEMENTS OF OPERATIONS (UNAUDITED) FOR THE NINE MONTHS ENDED SEPTEMBER 30,
2006 AND 2005.
<TABLE>
<CAPTION>
                                            FOR NINE MONTHS           FOR NINE MONTHS
                                                ENDED                     ENDED
                                               SEPT 30,                  SEPT 30,
                                                 2006                      2005                 2006 VS 2005
                                              ----------                ----------              ------------
                                             (UNAUDITED)                (UNAUDITED)         INCREASE/ (DECREASE)
<S>                                           <C>          <C>          <C>          <C>        <C>               <C>
Revenue
      Products                                $  291,651    78%         $  957,161    89%       $  (665,510)       -70%
      Service rendered                            84,611    22%            116,030    11%           (31,419)       -27%
                                              ----------                ----------              -----------
         Total revenue                           376,262   100%          1,073,191   100%          (696,929)       -65%
                                              ----------                ----------              -----------
Cost of sales
      Products                                   138,837                   158,118                  (19,281)       -12%
      Service rendered                             3,417                    11,677                   (8,260)       -71%
                                              ----------                ----------              -----------
        Total cost of sales                      142,254    38%            169,795    16%           (27,541)       -16%
                                              ----------                ----------              -----------
Gross profit                                     234,008    62%            903,396    84%          (669,388)       -74%
                                              ----------                ----------              -----------
Operating expenses:
      Selling and distribution expenses           84,510                    54,854                   29,656         54%
      General and administrative expenses        457,560                   511,831                  (54,271)       -11%
                                              ----------                ----------              -----------
Total operating expenses                         542,070   144%            566,685    53%           (24,615)        -4%
                                              ----------                ----------              -----------
Income from operations                          (308,062)  -82%            336,711    31%          (644,773)      -191%
                                              ----------                ----------              -----------
Other income/(expense)
      Interest income                            195,696                     2,529                  193,167       7638%
      Other (expense)/income, net                 10,663                    51,450                  (40,787)       -79%
                                              ----------                ----------              -----------
Total other (expense)/ income                    206,359    55%             53,979     5%           152,380        282%
                                              ----------                ----------              -----------
Income before income taxes                      (101,703)                  390,690                 (492,393)      -126%
Income taxes (expenses)/benefit                       --                    34,694                  (34,694)
                                              ----------                ----------              -----------
Income before minority interest                 (101,703)  -27%            355,996    33%          (457,699)      -129%
Minority Interest                                 (5,259)   -1%             82,760     8%           (88,019)      -106%
                                              ----------                ----------              -----------
Net income                                    $ (96,444)   -26%         $  273,236    25%       $  (369,680)      -135%
                                              ----------                ----------              -----------
</TABLE>

NINE MONTHS ENDED SEPTEMBER 30, 2006
COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2005

Net Sales

Cybrdi generates two categories of revenues: tissue chip product and services.
The net sales decrease to $376,262 or the nine months ended September 30, 2006
from $1,073,191 for the nine months ended September 30, 2005.

Tissue Chip Product: sales decreased along all product lines in the tissue chip
business. The net sales decreased $665,510to $291,651 for the nine months ended
September 30, 2006 as compared to $957,161 for the nine months ended September
30, 2005. The decrease in net sales of our Tissue Chip business is primarily
attributable to the company's new sales policy of restricting the sales to
certain existing customers in China with significantly delinquent past due
amounts. The decrease is partially offset by an increase in international sales.
Sales volume for Tissue Chip Products in China has dropped for the nine months
ended September 30, 2006 as compared to September 30, 2005. International sales
volume increased for the nine months ended September 30, 2006 as compared to
September 30, 2005.

Services: Fewer technical service orders were received during the first ,second
and third quarter of 2006 as compared to 2005 resulting in a decrease in sales
of $31,419 declining to $84,611 from $116,030 for the nine months ended
September 30, 2006 as compared to September 30, 2005.

                                       14
<PAGE>

Gross Margin

Gross margin as a percent of sales was 62% and 84% for the nine months ended
September 30, 2006 and 2005, respectively. Gross profit for the nine months
ended September 30, 2006 decreased to $234,008 from $903,396 for the nine months
ended September 30, 2005. The primary reason for the decrease was due to
decreased sales of Tissue Chip Products in China. This again was partially
offset by increased international sales of Tissue Chip Products. The gross
margin decrease was primarily due to the reduction in units of product sales.

Operating Expenses

Our operating expenses decreased $24,615 to $542,070 for the nine months ended
September 30, 2006 from $566,685 for the nine months ended September 30, 2005.
This is primarily due to an increase in selling and distribution expenses of
$29,656 to $84,510 for the nine months ended September 30, 2006 from $54,854 for
the nine months ended September 30, 2005, and was partially due to an decrease
in general and administrative expenses of $54,271 to $457,560 for the nine
months ended September 30, 2006 from $511,831 for the nine months ended
September 30, 2005. The decrease in general and administrative expenses was
primarily due to the reduction of office expenses, consulting fee, professional
expenses, travel expenses, and depreciation for deferred assets in year 2006.
The increase in selling expenses is primary due to the membership fee $34,159
(RMB273,555) allocated from Tinmei Lelier Slim Body Medical Tech for nine months
ended September 30, 2006 for the Company to use Lelier's trade mark, technology
and products. The effective period for this membership is from November 10th
2005 to December 31, 2007. For the period from November 10th 2005 (date of
membership start) to September 30, 2006, the Company did not generate any income
from this membership

Income Taxes

The Company has not recorded a provision for federal income tax for quarter
ended September 30, 2006 due to no taxable income incurred for nine months ended
September 30, 2006. In accordance with the relevant tax laws and regulations of
the People's Republic of China, Chaoying Biotech is entitled to full exemption
from Corporation Income Tax ("CIT") for the first two years and a 50% reduction
in CIT for the next six years, commencing from the first profitable year after
offsetting all tax losses carried forward from the previous five years. As 2003
was Chaoying Biotech's first profitable year, the Company begins to record 50%
CIT provision from the first quarter of 2005. The effective income tax rate is
7.5% for the quarter ended September 30, 2006 and 2005. Due to operating losses
for the nine months ended September 30, 2006, the Company does not need to pay
income tax for the quarter ended September 30, 2006.

LIQUIDITY AND CAPITAL RESOURCES

Operating working capital (accounts receivable plus inventory less accounts
payable) decreased by $338,640 from $590,019 as of December 31, 2005 to
$251,379, as of September 30, 2006. The decrease was primarily due to a decrease
in accounts receivable of $354,922 from $360,503, at December 31, 2005 to $5,581
at September 30, 2006, and an increase in accounts payable of $38,683, from
$34,118 at December 31, 2005 to $72,801, at September 30, 2006, which was offset
by an increase in inventory of $54,965 from $263,634 at December 31, 2005 to
$318,599 at September 30, 2006. Decrease in net sales on Tissue Chip Product as
result of the Company's new sales policy is attributable to the decrease in
account receivables and increase in inventories. The increase in accounts
payables and accrued expenses is primary due to unpaid professional fees of
$.40,650.

The Company has $42,637 and $15,623 capital fix assets expenditure for the nine
months ended September 30, 2006 and 2005. Included in investing activities is
also a loan to unaffiliated company of $3,200,911 for nine months ended
September 30, 2006. Financing activities for the nine months ended September
30, 2006 consumed $411,655 reflecting a repayment of advance to shareholders,
and received $1,000 proceeded advanced from shareholders.

                                       15
<PAGE>

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-QSB contain or may
contain forward-looking statements that are subject to known and unknown risks,
uncertainties and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. These
forward-looking statements were based on various factors and were derived
utilizing numerous assumptions and other factors that could cause our actual
results to differ materially from those in the forward-looking statements. These
factors include, but are not limited to, economic, political and market
conditions and fluctuations, government and industry regulation, interest rate
risk, U.S. and global competition, and other factors. Most of these factors are
difficult to predict accurately and are generally beyond our control. You should
consider the areas of risk described in connection with any forward-looking
statements that may be made herein. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of
this report. Readers should carefully review this quarterly report in its
entirety, including but not limited to our financial statements and the notes
thereto. Except for our ongoing obligations to disclose material information
under the Federal securities laws, we undertake no obligation to release
publicly any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events. For any forward-looking
statements contained in any document, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

Critical Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
materially from those estimates.

The preparation of financial statements in conformity with generally accepted
accounting principles (GAAP) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results may differ from those estimates.

Revenue recognition: Revenue represents the invoiced value of goods sold
recognized upon the delivery of goods to customers and service income is
recognized when services are provided. Deferred revenue represents the
undelivered portion of invoiced value of goods sold to customers. Sales
transactions not meeting all the conditions of the full accrual method are
accounted for using the deposit method of accounting. Under the deposit method,
all costs are capitalized as incurred, and payments received from the buyer are
recorded as customer deposits.

                                       16
<PAGE>

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Exchange Risk

         The majority of our net sales, costs and expenses are priced in Chinese
renminbi. Our assets are predominantly located inside China. Since 1994, the
exchange rate for Renminbi against the United States dollar has remained
relatively stable, with an exchange rate approximately RMB8.28 to US$1.00. On
July 21, 2005, China announced a revaluation of RMB and dropped its peg to the
US dollar. China has moved to a managed float against a basket of currencies.
The exchange rate has been marginally fluctuated since then. However, there can
be no assurance that Renminbi will not be subject to devaluation. We may not be
able to hedge effectively against Renminbi devaluation, so there can be no
assurance that future movements in the exchange rate of Renminbi and other
currencies will not have an adverse effect on our financial condition.

Item 4.  Controls and Procedures

         An evaluation was carried out by the Company's chief executive officer
and treasurer of the effectiveness of the Company's disclosure controls and
procedures (as defined in Rule 13a-15e or 15(d)-15(e) of the Securities Exchange
Act of 1934) as of September 30, 2006. Based upon that evaluation, the chief
executive officer and the treasurer concluded that the design and operation of
these disclosure controls and procedures were effective after giving affect to
the acquisition of Cybrdi, Inc. by the Company and its obligations to comply
with applicable accounting and disclosure requirements.









                                       17

<PAGE>

                           PART II. OTHER INFORMATION


Item 1.  Legal Proceedings

         There is no material pending legal proceedings to which the Company is
a party. The Company was notified by a letter dated June 2, 2000 that the
Company may have a potential liability from waste disposal in the Casmalia
Disposal Site at Santa Barbara County, California. The Company was given a
choice of either signing an agreement that would toll the statute of limitations
for eighteen (18) months in order to allow the Company to resolve any liability
with the government without incurring costs associated with being named a
defendant in a lawsuit, or becoming an immediate defendant in a lawsuit. The
Company signed the tolling agreement. On November 20, 2001, the tolling
agreement was extended for an additional 18 months. On May 20, 2003 the tolling
agreement was again extended for an additional 18 months and on November 24,
2004 the tolling agreement was again extended for additional 18 months. On June
29, 2004, the Company received a proposed settlement from the EPA in the amount
of $21,131. The Company is waiting for communication from the government
concerning payment of the proposed settlement. As of September 30, 2006, the
Company has accrued a sufficient amount to cover any potential liabilities from
this matter.

Item 2.  Unregistered Sales of Equity Securities,

         None.

Item 3.  Defaults upon senior securities.

         None.

Item 4.  Submission of matters to a vote of security holders.

         None.

Item 5.  Exhibits and Report on Form 8-K

(a)      Exhibits:

       31.1     Rule 13(a)-14(a)/15(d)-14(a) Certification

       31.2     Rule 13(a)-14(a)/15(d)-14(a) Certification

       32.1     Certification Under Section 906 of the Sarbanes-Oxley Act
                of 2002

       32.2     Certification Under Section 906 of the Sarbanes-Oxley Act
                of 2002

(b)      Reports on Form 8-K:

         None.

                                       18
<PAGE>
                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                              CYBRDI, INC.


DATE:  December 27, 2006                      /s/ Yanbiao Bai
                                              ---------------
                                              Yanbiao Bai
                                              Chief Executive Officer and
                                              President











                                       19